On the basis of the high concordance between radiological data and pathological findings, high-resolution magnetic resonance imaging (MRI) has become the gold standard for rectal cancer staging and assessment of baseline risk factors such as threatening/involvement of the mesorectal fascia and extramural venous invasion (EMVI) ([@bib3]; [@bib6]). Routine use of MRI has led to the implementation of selective management strategies including surgery alone for patients with low-risk tumours (⩽T2, N0, and no risk factors) or neoadjuvant therapy (i.e., long-course chemo-radiotherapy or short-course radiotherapy depending on the need of tumour downsizing/downstaging) followed by surgery for those at higher risk of tumour recurrence (i.e., ⩾T3 and/or N+ stage, and/or other risk factors) ([@bib13]; [@bib22]).

Magnetic resonance imaging has also played an increasingly important role in the assessment of response to neoadjuvant treatment and surgical planning ([@bib2]; [@bib21]; [@bib35]). A number of imaging parameters have been proposed to assess the degree of tumour response including linear, bi-dimensional or volumetric changes of the primary tumour and T/N downstaging ([@bib16]; [@bib15]; [@bib40]; [@bib23]; [@bib41]; [@bib39]). More recently, based on the ability to distinguish between areas of residual cancer and treatment-induced fibrosis (i.e., intermediate signal intensity and low signal intensity, respectively, on T2-weighted images) and estimate the relative proportion of these within the treated tumour mass, an imaging-based, tumour regression scoring system (i.e., mrTRG) has been developed ([@bib24]) that follows the principles of the pathological tumour regression grading (pTRG) proposed by [@bib19] and [@bib12].

The main advantage of mrTRG is that it does not rely on the assessment of the resection specimens. The degree of tumour regression on MRI can be assessed before any surgical procedure is performed, this information potentially providing an opportunity window to consider salvage pre-operative treatments if satisfactory tumour regression is not achieved with standard therapy or adoption of a non-operative management strategy if complete response with no active residual cancer is diagnosed ([@bib14]; [@bib18]; [@bib26]; [@bib28]; [@bib30]). Furthermore, if appropriate training is undertaken, assessing tumour regression changes on imaging scans may prove to be highly reproducible ([@bib33]) and potentially overcome some of the limitations of pTRG including the need for accurate pathological sampling, subjective interpretation and inter-observer variability ([@bib17]; [@bib8], [@bib9]). Nevertheless, while the prognostic value of pTRG in rectal cancer has been largely confirmed and validated across a number of patient series and using a variety of classification systems, fewer studies have analysed the association between mrTRG and outcome in this setting ([@bib37]; [@bib32]). Also, little information is currently available regarding the correspondence between imaging and pathological tumour regression changes in individual patients as well as the prognostic significance of mrTRG in patients who undergo surgery and are therefore assessable for pTRG.

In a recent report of Pooled Analysis of Individual Clinical and Molecular Data of Two Trials of Neoadjuvant Chemotherapy in High-Risk Rectal Cancer, EXPERT and EXPERT-C (PAN-EX), we have shown that, in a population of high-risk, locally advanced rectal cancer patients who were treated with an intensified neoadjuvant treatment including induction chemotherapy followed by chemo-radiotherapy, both mrTRG and pTRG were prognostic for relapse-free survival (RFS), distant relapse-free survival (DRFS) and overall survival (OS) in univariate analyses ([@bib29]). However, in multivariate analyses, only mrTRG retained its prognostic role. Here we report the correlation between mrTRG and pTRG as assessed in individual patients from this study and investigate the prognostic value of mrTRG in pTRG-defined patient subgroups.

Materials and methods
=====================

PAN-EX was a pooled analysis of two academic phase II trials, EXPERT and EXPERT-C ([@bib29]). EXPERT was a single-centre, single-arm, phase II trial conducted at The Royal Marsden NHS Foundation Trust between 2001 and 2005. EXPERT-C was an international, multicentre, randomised phase II trial conducted at 12 sites across the UK, Sweden and Spain between 2005 and 2008. Both studies were restricted to non-metastatic rectal cancer patients with at least one of the following high-risk features on high-resolution pelvic MRI: tumour ⩽1 mm of the mesorectal fascia, extramural invasion \>5 mm (T3c/d), T4 stage, T3 tumour at/below levators. Additional eligibility criteria included N2 stage (EXPERT) and EMVI (EXPERT-C) ([@bib7]; [@bib10]; [@bib11]).

All patients received neoadjuvant treatment including four cycles of induction CAPOX chemotherapy followed by capecitabine-based chemo-radiotherapy (54 Gy in EXPERT and 50.4 Gy in EXPERT-C). Total mesorectal excision was performed 4--6 weeks after completion of chemo-radiotherapy and followed by four cycles of adjuvant chemotherapy (single agent capecitabine in EXPERT and CAPOX in EXPERT-C). Cetuximab was also administered throughout the study treatment in patients who were randomised (1 : 1 ratio) to the investigational arm of the EXPERT-C trial.

High-resolution MRI of the pelvis was done at baseline, at the end of induction chemotherapy and 4 weeks after completion of chemo-radiotherapy. All study MRI scans were centrally assessed by one radiologist (G.B.) who was blinded to the pathological data and long-term patient outcomes. MRI scans from EXPERT-C were prospectively assessed while MRI scans from EXPERT were retrospectively reviewed. mrTRG was defined as previously reported ([@bib24]). For the assessment of pTRG, the recommendations by Dworak were followed ([@bib12]). Generally, a minimum of five blocks or 5--8 mm thick slices were obtained from areas of macroscopic residual tumour and suspect area of fibrotic tissue (if no macroscopic residual tumour), respectively, in formalin fixed resected specimens. Three- to 5-μm thick, haematoxylin and eosin slides from each block were prepared and examined. If no tumour was found on the first slide a step section technique was used and three levels were cut on all blocks from the tumour site; if still no tumour was found, the whole of the tumour site and/or the fibrotic area was blocked. pTRG was assessed by local independent pathologists who were blinded to the imaging data. Assessment of pTRG was done prospectively in EXPERT-C and retrospectively in EXPERT. Both the imaging and the pathological system used to score TRG in this study assess the relative proportion of fibrosis and residual cancer and categorise tumour response using a five-tier scale in the reverse order ([Table 1](#tbl1){ref-type="table"}). Only patients who were assessable for both mrTRG after chemo-radiotherapy and pTRG on resection specimens having undergone resection of the primary tumour with a curative intent (R0/R1 resection) were included in this analysis.

EXPERT and EXPERT-C were approved by the relevant National Regulatory Agencies and Research Ethics Committee. All patients provided written informed consent. The PAN-EX study was approved by the Committee for Clinical Research at The Royal Marsden NHS Foundation Trust.

Statistical analysis
--------------------

The strength of agreement between mrTRG after completion of neoadjuvant treatment and pTRG on the resection specimens was assessed using the weighted *κ* test (*κ* value \<0.20: poor agreement; *κ* value=0.21--0.40: fair agreement; *κ* value=0.41--0.60: moderate agreement; *κ* value=0.61--0.80: good agreement; *κ* value=0.81--1.00: very good agreement). This analysis was conducted considering the pre-defined five categories of tumour regression as well as converting the above described five-tier regression systems into three-tier regression systems (i.e., pTRG 0--1 *vs* pTRG 2 *vs* pTRG 3--4 and mrTRG 4--5 *vs* mrTRG 3 *vs* mrTRG 1--2). Furthermore, correlation between prognostic categories as defined by each regression system was also investigated in an exploratory analysis. Sensitivity, specificity, positive predictive value and negative predictive value of mrTRG were calculated using a dichotomous classification for both mrTRG (i.e., mrTRG 3--5 *vs* mrTRG 1--2) and pTRG (i.e., pTRG 0--3 *vs* pTRG 4) to assess the ability of MRI to identify pathological complete responders. Finally, the agreement between two radiologists in the assessment of mrTRG (i.e., mrTRG 3--5 *vs* mTRG 1--2) was analysed in a subset of randomly selected patients from the EXPERT-C study using the weighted *κ* test as above described.

Relapse-free survival and OS were calculated from date of surgery to date of recurrence and death, respectively. Patients alive and without evidence of tumour recurrence were censored at last follow-up. Patients who died without tumour recurrence were censored at the time of death. The Kaplan--Meier method was used to estimate the survival outcome. Software used was SPSS 24 and Stata 14.

Results
=======

The PAN-EX study included 269 patients (105 from the EXPERT trial and 164 from the EXPERT-C trial). Of these, 240 underwent resection of the primary tumour with a curative intent (i.e., R0 resection in 233 cases while R1 resection in seven cases). Radiological tumour regression on post-chemo-radiotherapy MRI scan (i.e., mrTRG) and pathological tumour regression on surgical specimens (i.e., pTRG) was reported for 215 and 208 patients, respectively. A total of 191 patients (79.6%) were assessable for both mrTRG and pTRG and represented the study population. Patient demographics and baseline characteristics are shown in [Table 2](#tbl2){ref-type="table"}. No significant differences were observed compared with the overall PAN-EX population (data not shown). The median time from the end of chemo-radiotherapy to the pre-operative MRI scan was 4.1 weeks (IQR: 3.7--4.7). The median time from the end of chemo-radiotherapy to surgery was 6.6 weeks (IQR: 5.9--7.6). The median time from the pre-operative MRI scan to surgery was 2.6 weeks (IQR: 1.7--3.7).

In 64 out of 191 cases (33.5%) radiologist and pathologist quantitated tumour regression using specular regression categories. Overall agreement between mrTRG and pTRG using weighted *k* analysis was 71.0% (*k*: 0.24) ([Table 3](#tbl3){ref-type="table"}). In the group of patients for whom disagreement was due to a substantially more pronounced regression on imaging than pathology specimens (i.e., mrTRG 1/pTRG 0--2, mrTRG 2/pTRG 0--1, mrTRG 3/pTRG 0; *n*=24) the median time from pre-operative MRI scan to surgery was 2.7 weeks (IQR: 2.0--3.5). In the group of patients for whom disagreement was due to a substantially more pronounced regression on pathology specimens than imaging (i.e., mrTRG 5/pTRG 2--4, mrTRG 4/pTRG 3--4, mrTRG 3/pTRG 4; *n*=16) the median time from pre-operative MRI scan to surgery was 2.1 weeks (IQR: 1.1--3.9). In the remaining patients (*n*=151) this interval was 2.4 weeks (IQR: 1.7--3.7). When only three categories were considered for each regression system, 88/191 patients (46.1%) were classified as having specular degree of tumour regression on imaging and pathology for an overall agreement of 66.0% (*k*: 0.25).

Previous analyses of the PAN-EX study showed that patients who had achieved mrTRG 1--2 after completion of chemo-radiotherapy had a significantly better prognosis than the remaining patient population without any difference between mrTRG 3 and mrTRG 4--5. In contrast, the assessment of pathological regression with the Dworak system allowed identification of a group (pTRG 2) with an intermediate prognosis between patients with pTRG 0--1 and those with pTRG 3--4 ([@bib29]). 44 out of 87 patients (50.6%) belonging to the favourable prognosis group based on the degree of radiological tumour regression (mrTRG 1--2) were also found to have a good pathological tumour regression (pTRG 3--4), the remaining patients being classified as having a pTRG of 2 (31.0%) or 0--1 (18.4%). Among 104 patients with predicted poor prognosis due to suboptimal tumour regression on pre-operative MRI scan (mrTRG 3--5), 49 (47.1%) were confirmed to have minimal pathological tumour regression (pTRG 0--1), while 31 (29.8%) and 24 (23.1%) showed a pTRG of 2 and 3--4, respectively. When a dichotomous classification (i.e., pTRG 0--3 *vs* pTRG 4 and mrTRG 3--5 *vs* mrTRG 1--2) was used to assess the ability of MRI to predict complete regression, 32 out of 43 patients (74.4%) with pathological complete response were correctly identified using mrTRG. Sensitivity, specificity, positive predictive value and negative predictive value of mrTRG were 74.4% (95% CI: 58.8--86.5), 62.8% (95% CI: 54.5--70.6), 36.8% (95% CI: 26.7--47.8) and 89.4% (95% CI: 81.9--94.6), respectively. MRI scans of 25 randomly selected patients from the EXPERT-C study were reviewed by two radiologists (G.B. and S.B.) to assess inter-observer variability in the assessment of complete/almost complete responders (i.e., mrTRG 1--2 *vs* mrTRG 3--5) and a very good agreement was observed (weighted *k* agreement: 92.0% *k*: 0.84).

The median follow-up of the study population at the time when the analysis was conducted was 65.5 months (95% CI: 65.1--66.2; range 1.5--122.0 months). [Table 4](#tbl4){ref-type="table"} shows the outcome of pTRG-defined patient subgroups according to the degree of radiological tumour regression achieved after chemo-radiotherapy. While mrTRG did not have any influence on the good prognosis of patients with a pTRG of 3--4, it appeared to have a non-statistically significant impact especially on the outcome of those who were classified as having moderate pathological regression. In this group 5-year RFS and OS rates were 65.9% and 68.8%, respectively, if mrTRG after chemo-radiotherapy was 3--5, and 76.9% (pairwise comparison *P* value=0.180) and 80.6% (pairwise comparison *P* value=0.220) if mrTRG after chemo-radiotherapy was 1--2. [Table 5](#tbl5){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"} show long-term outcomes of patients who were classified by combining mrTRG and pTRG and splitting the intermediate pathological tumour regression group (pTRG 2) into two subgroups depending on the degree of tumour regression on imaging.

Discussion
==========

To our knowledge, this is the largest study assessing the agreement between an MRI-based tumour regression grading system and the classical pTRG system as proposed by Dworak *et al* in a largely homogenous series of locally advanced rectal cancer patients. The results of our analysis overall suggest that limited correspondence exists between regression groups/prognostic categories as identified by such classification methods. Nevertheless, they support the contention that mrTRG may potentially be used as an imaging parameter to select good-prognosis patients who could be managed with a non-operative approach following neoadjuvant treatment. Furthermore, information on the degree of tumour regression on the pre-operative MRI may be of prognostic value after surgical resection in specific pTRG patient subgroups.

Monitoring treatment efficacy has a central role in the management of cancer patients. Assessing the effects of treatment is not only important to define treatment duration but it has also the potential to provide useful prognostic information and guide subsequent therapeutic and/or follow-up strategies. This is certainly relevant to rectal cancer where neoadjuvant therapy is routinely used for locally advanced tumours to increase the chances of surgical resection with clear margins and/or to reduce the risk of local recurrence ([@bib5]; [@bib27]). Meticulous assessment of the surgical samples was proposed more than two decades ago to provide a semi-quantitative estimate of the degree of tumour regression with prognostic implications ([@bib19]; [@bib12]) and pTRG is now regularly included in pathology reports. Nevertheless, its clinical usefulness remains limited for a number of reasons. First of all, assessment of response to neoadjuvant treatment by pTRG is only possible in patients who undergo resection and only after a surgical procedure has been performed. Furthermore, the potential of pTRG to capture the heterogeneity of tumour response to chemo-radiotherapy and overcome the simplistic distinction between complete responders and noncomplete responders has inevitably translated into a relatively low inter-observer reproducibility of the same ([@bib17]; [@bib8], [@bib9]). The availability of a variety of pTRG scoring systems has enhanced this inconvenience and also reduced comparability between series. Finally, despite a promising premise, the impact of pTRG on the management of rectal cancer is still limited as there is still no evidence to suggest that tailoring post-operative treatments based on the degree of pathological regression may improve outcome.

Advances in imaging have provided an opportunity to use novel, alternative methods for the assessment of tumour response to neoadjuvant chemo-radiotherapy. mrTRG has recently emerged as a dynamic, non-invasive, surrogate method for the assessment of tumour regression following neoadjuvant treatment and before surgical resection ([@bib24]). Studies have shown its ability to predict pathological findings on the surgical specimens as well as long-term prognosis ([@bib24]; [@bib31]; [@bib4]; [@bib32]). Also, both in routine practice ([@bib29]) and adaptive clinical trials (NCT02704520) mrTRG has been increasingly used as a decision-making tool for patient management following completion of standard neoadjuvant chemo-radiotherapy.

Nevertheless, one of the questions that remain unanswered regarding mrTRG is whether and to what extent this truly reflects the degree of pathological regression that will be observed once surgery has been carried out. In this study we have shown that, even though tumour regression on imaging is measured according to a five-tier scoring system mirroring the scoring system that is used for the assessment of pathological regression, the agreement between radiologists and pathologists is overall limited. This did not appear to be any better when regression groups with similar prognosis across the two scoring systems (instead of the pre-defined categories of regression) were directly compared. While these results are in line with other studies ([@bib38]) and appear to suggest that mrTRG cannot be considered as an accurate predictor of pTRG, it should be noted that the time interval between chemo-radiotherapy and surgery in our series was longer than that between chemo-radiotherapy and MRI (difference between median values: 2.5 weeks) this possibly accounting for some of the observed discrepancies. Response to chemo-radiotherapy is a continuum process with the peak of tumour regression being estimated to occur ∼8--11 weeks after treatment completion ([@bib34]; [@bib25]; [@bib36]). Therefore, it is possible that the early timing of MRI assessment in this patient population may have precluded the anticipated category shift in tumour regression and ultimately affected the agreement between mrTRG and pTRG. In support of this contention, the proportion of study patients achieving complete regression on resection specimens was almost twice as high as that on imaging (i.e., 13.6% *vs* 7.3%). On the other hand, while cases where poor pathological regression was reported despite complete or almost complete absence of intermediate signal intensity on pre-operative imaging could raise the possibility of early tumour regrowth, the median interval between MRI scan and surgical resection in this patient subgroup (2.7 weeks *vs* 2.5 in the overall population) mitigates against this hypothesis. We believe that these cases are more likely to be secondary to a reduced specificity of MRI after neoadjuvant treatment ([@bib20]). Finally, it is also possible that the investigational, intensified neoadjuvant treatment strategies that were used in the PAN-EX study might have had an impact on the limited correspondence between mrTRG and pTRG. For instance, in contrast with what we have previously reported in studies with conventional chemo-radiotherapy ([@bib24]), only two (instead of three) mrTRG prognostic groups could be identified in the PAN-EX population where a regression category with intermediate prognosis was lacking ([@bib29]).

Even accounting for the above mentioned biases, one could argue that the lack of substantial correspondence between tumour regression as identified by imaging and pathology may undermine the clinical value of mrTRG. It should be noted, however, that the prognostic role of this imaging parameter has already been validated in a number of series and in the PAN-EX study itself mrTRG (but not pTRG) emerged as an independent factor for RFS, DRFS and OS in the curatively resected population ([@bib31]; [@bib4]; [@bib29]; [@bib32]). Moreover, the main value of using mrTRG is to provide a non-invasive imaging tool to identify those patients who are more likely to achieve complete response to treatment and therefore may be spared from surgery ([@bib14]; [@bib18]; [@bib26]). In our series, the sensitivity and specificity of mrTRG to identify pathological complete response was 74.4% and 62.8%, respectively. While these data appear less encouraging compared to previous reports ([@bib4]), it should be noted that in this study more stringent criteria (i.e., mrTRG 1--2) for the definition of complete response according to imaging were used excluding mrTRG 3 tumours that may actually continue to regress beyond the date of MRI scan. Furthermore, repeat assessment of mrTRG on serial MRI scans to follow the evolution of tumour regression over time is more clinically relevant than a snapshot of mrTRG at a single time point and likely to increase the overall accuracy of this imaging marker in predicting pathological complete response. In this regard it is worth noting that, using a subset of study patients, we have confirmed the results of previous studies regarding the reproducibility of mrTRG ([@bib33]) and showed a very good agreement between radiologists in the assessment of complete or almost complete tumour regression.

The results of our study suggest that, despite similar nomenclature and categorisation system, mrTRG and pTRG are not interchangeable parameters but have the potential to provide complementary information regarding sensitivity of the primary tumour to neoadjuvant treatment and overall outcome. Of interest, patients who had not achieved substantial/complete regression according to the pathology report could be further stratified for the risk of tumour recurrence and death based on the degree of tumour regression as assessed on imaging at the end of chemo-radiotherapy. This effect appeared possibly stronger for those who were categorised as having a pTRG of 2 and therefore expected to have intermediate prognosis. While these data are certainly intriguing, it should be acknowledged that the impact of mrTRG on the prognosis of patients with sub-optimal pathological regression was only numerical but not statistically significant possibly due to the small sample size of the study. Larger series are needed to confirm these hypothesis-generating findings and better assess the clinical relevance of mrTRG in patients who undergo surgical resection and are therefore assessable for standard pTRG.

Intra- and inter-observer reproducibility is an established caveat of semi-quantitative scoring systems. A number of studies have demonstrated that achieving consensus on the degree of tumour regression in resection specimens among pathologists is particularly challenging ([@bib17]; [@bib8], [@bib9]). While the assessment of pTRG by local pathologists suggests that the pathological data from PAN-EX are reflective of real-world practice, the lack of a centralised review (in contrast with the radiological assessment) may have introduced significant biases. mrTRG appears to be less prone to inter-observer variability among specifically trained radiologists ([@bib24]), as confirmed by the analysis of a subset of patients from our study. The assessment of mrTRG, however, may be still potentially affected by a certain degree of subjective interpretation. Therefore, the results of our study should be interpreted in view of these inherent limitations. It is possible that the findings here reported may not be confirmed in series from other institutions. Nevertheless, the mrTRG scoring system, which was first proposed by our group, has been routinely used for several years at our institution and pTRG in PAN-EX was assessed by highly experienced pathologists, thus increasing the reliability of our study. Also, the use of a weighted *k* test to compare radiological and pathological assessment should have accounted for some inter-observer variability and increased the generalisability of our results. Finally, given the similarities between all the available pTRG scoring systems both in terms of classification criteria and prognostication ([@bib37]), it is unlikely that classifying pathological tumour regression according to a different method would change the outcome of the analysis.

In conclusion, while the retrospective design of the study and the above mentioned caveats recommend caution in the interpretation of our findings, this analysis suggests that the agreement between mrTRG and pTRG is low and thus mrTRG cannot be considered as a reliable surrogate imaging marker of pTRG in locally advanced rectal cancer patients who undergo an intensified neoadjuvant treatment. Nevertheless, given the ability to provide a non-invasive assessment of tumour response, mrTRG remains a potential tool for the implementation of dynamic, risk-adapted, neoadjuvant treatment strategies following standard chemo-radiotherapy including deferral of surgery/watch and wait or further (i.e., sequential/salvage) therapy. Assessing the degree of tumour regression on pre-operative MRI scans may potentially serve also as a useful parameter to combine with conventional pathological factors to refine prognostication and possibly guide adjuvant treatments/follow-up strategies after surgical resection. It should be noted, however, that mrTRG is only one of the available methods to assess and categorise tumour response to neoadjuvant treatment and its significance should be interpreted in the context of other well-established imaging parameters. Furthermore, mrTRG is regularly reported only in a limited number of centres and further studies to investigate its clinical applications are warranted.
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![**Kaplan--Meier curves for recurrence-free survival (A) and overall survival (B) by combining mrTRG and pTRG.**](bjc2017320f1){#fig1}

###### Classification system for mrTRG and pTRG

  **mrTRG**                                                                                                                        **pTRG**           
  ------------------------------------------------------------------------------------------------------------------------------- ---------- -------- ---------------------------------------------------------------------------------------------------------------
  No regression (intermediate signal intensity, same appearances as original tumour)                                               mrTRG 5    pTRG 0  No regression
  Slight regression (little areas of low signal intensity fibrosis or mucin but mostly tumour)                                     mrTRG 4    pTRG 1  Dominant tumour mass with obvious fibrosis and/or vasculopathy
  Moderate regression (low signal intensity fibrosis predominates but there are obvious areas of intermediate signal intensity)    mrTRG 3    pTRG 2  Dominantly fibrotic changes with few tumour cells or groups (easy to find)
  Good regression (predominant low signal intensity fibrosis with no obvious residual tumour signal)                               mrTRG 2    pTRG 3  Very few (difficult to find microscopically) tumour cells in fibrotic tissue with or without mucous substance
  Complete regression (absence of tumour signal and barely visible treatment related scar)                                         mrTRG 1    pTRG 4  No tumour cells, only fibrotic mass (total regression or response)

Abbreviations: mrTRG=magnetic resonance tumour regression grade; pTRG=pathological tumour regression grade.

###### Demographics and baseline characteristics

                                                                   ***N***   **%**
  ---------------------------------------------------------------- --------- --------
  **Gender**                                                                 
  Male                                                             108       56.5
  Female                                                           83        43.5
  Age (yrs) (median & range)                                       63        31--80
  **ECOG performance status**                                                
  0                                                                81        42.4
  1--2                                                             110       57.6
  **Tumour differentiation**                                                 
  Well or moderately differentiated                                163       85.3
  Poorly differentiated                                            20        10.5
  Missing                                                          8         4.2
  **Tumour location**[a](#t2-fn2){ref-type="fn"}                             
  High rectum                                                      69        36.1
  Mid rectum                                                       78        40.8
  Low rectum                                                       44        23.0
  Length of tumour[a](#t2-fn2){ref-type="fn"} (mm) (mean & s.d.)   54.4      15.8
  **T stage**[a](#t2-fn2){ref-type="fn"}                                     
  2                                                                5         2.6
  3[b](#t2-fn3){ref-type="fn"}                                     144       75.4
  4                                                                42        22.0
  **N stage**[a](#t2-fn2){ref-type="fn"}                                     
  0                                                                61        31.9
  1                                                                64        33.5
  2                                                                66        34.6
  MRF threatened/involved[a](#t2-fn2){ref-type="fn"}               111       58.1
  EMVI positive[a](#t2-fn2){ref-type="fn"}                         136       71.2

Abbreviations: ECOG=Eastern Cooperative Oncology Group; EMVI=extramural venous invasion; MRF=mesorectal fascia; mrTRG=magnetic resonance tumour regression grade; pTRG=pathological tumour regression grade; s.d.=standard deviation.

Assessed by MRI (high: \>10 cm from the anal verge; mid: \>5--10 cm from the anal verge; low: ≤5 cm from the anal verge).

117/144 (81.3%) patients with T3 tumours had \>5 mm mesorectal infiltration (i.e., T3c or T3d tumours).

###### Comparison between mrTRG and pTRG

                                                    **mrTRG**[a](#t3-fn2){ref-type="fn"}                       
  ------------------------------------- ----------- -------------------------------------- ---- ---- ---- ---- -----
  **pTRG**[b](#t3-fn3){ref-type="fn"}   **0**       0                                      4    4    1    0    9
                                        **1**       4                                      17   20   13   2    56
                                        **2**       0                                      12   19   23   4    58
                                        **3**       0                                      6    8    24   4    42
                                        **4**       0                                      5    5    12   4    26
                                        **Total**   4                                      44   56   73   14   191

Abbreviations: mrTRG=magnetic resonance tumour regression grade; pTRG=pathological tumour regression grade.

mrTRG 1 and mrTRG 5 indicate complete radiological regression and no radiological regression, respectively.

pTRG 4 and pTRG 0 indicate complete pathological regression and no pathological regression, respectively.

###### Prognostic impact of mrTRG in specific pTRG patient subgroups

  **Outcome measure**   **pTRG/mrTRG subgroup**     ***n*** **Events/*****n*** **subjects**  **5-year survival (95% CI)**    **Hazard ratio (95% CI)**   ***P*** **value**   **Pairwise** ***p*** **value**
  --------------------- -------------------------- ----------------------------------------- ------------------------------ --------------------------- ------------------- --------------------------------
  **RFS**               1\. pTRG 0--1/mrTRG 3--5                     23/49                   57.1 (43.2--71.0)                          1.0                   (0.023)                   1 *vs* 2
                        2\. pTRG 0--1/mrTRG 1--2                     6/16                    73.3 (50.9--95.6)                   0.64 (0.26--1.60)             0.34                      0.391
                        3\. pTRG 2/mrTRG 3--5                        11/31                   65.9 (48.7--83.1)                   0.85 (0.41--1.76)             0.65                     3 *vs* 4
                        4\. pTRG 2/mrTRG 1--2                        6/27                    76.9 (60.6--93.2)                   0.45 (0.18--1.11)             0.081                     0.180
                        5\. pTRG 3--4/mrTRG 3--5                     3/24                    87.3 (73.8--100)                    0.25 (0.07--0.84)             0.025                    5 *vs* 6
                        6\. pTRG 3--4/mrTRG 1--2                     8/44                    88.5 (78.9--98.1)                   0.30 (0.14--0.68)             0.004                     0.974
  **OS**                1\. pTRG 0--1/mrTRG 3--5                     21/49                   63.1 (49.6--76.6)                          1.0                   (0.053)                   1 *vs* 2
                        2\. pTRG 0--1/mrTRG 1--2                     5/16                    80.0 (59.8--100)                    0.57 (0.21--1.52)             0.260                     0.301
                        3\. pTRG 2/mrTRG 3--5                        10/31                   68.8 (51.7--85.9)                   0.83 (0.39--1.80)             0.638                    3 *vs* 4
                        4\. pTRG 2/mrTRG 1--2                        5/27                    80.6 (65.3--95.9)                   0.45 (0.17--1.20)             0.110                     0.220
                        5\. pTRG 3--4/mrTRG 3--5                     3/24                    91.7 (78.2--100)                    0.30 (0.09--1.00)             0.050                    5 *vs* 6
                        6\. pTRG 3--4/mrTRG 1--2                     7/44                    90.7 (82.1--99.3)                  0.31 (0.013--0.72)             0.007                     0.771

Abbreviations: CI=confidence interval; mrTRG=magnetic resonance tumour regression grade; OS=overall survival; pTRG=pathological tumour regression grade; RFS=recurrence-free survival.

###### Survival outcomes by combining mrTRG and pTRG

  **Outcome measure**   **pTRG/mrTRG subgroup**                  ***n*** **Events/*****n*** **subjects**  **5-year survival (95% CI)**    **Hazard ratio (95% CI)**  ***P*** **value**
  --------------------- --------------------------------------- ----------------------------------------- ------------------------------ --------------------------- -------------------
  **RFS**               pTRG 0--1/mrTRG any pTRG 2/mrTRG 3--5                     40/96                   62.7 (52.9--72.5)                          1.0             0.001
                        pTRG 2/mrTRG 1--2 pTRG 3--4/mrTRG any                     17/95                   86.0 (78.9--93.1)                   0.37 (0.21--0.66)       
  **OS**                pTRG 0--1/mrTRG any pTRG 2/mrTRG 3--5                     36/96                   67.5 (57.9--77.1)                          1.0             0.003
                        pTRG 2/mrTRG 1--2 pTRG 3--4/mrTRG any                     15/95                   88.1 (81.4--94.8)                   0.39 (0.22--0.72)       

Abbreviations: CI=confidence interval; mrTRG=magnetic resonance tumour regression grade; OS=overall survival; pTRG=pathological tumour regression grade; RFS=recurrence-free survival.
